Bristol Pravachol Ads Broaden Indication, FDA Warning Letter Says
Executive Summary
FDA is asking Bristol-Myers Squibb to correct Pravachol advertising claims that the agency says broadens the indication and patient populations for which the cholesterol-lowering agent is approved